Anti-NFkB p105 / p50 antibody, prediluted (ab15485)

Overview

  • Product nameAnti-NFkB p105 / p50 antibody, predilutedSee all NFkB p105 / p50 primary antibodies ...
  • Description
    Rabbit polyclonal to NFkB p105 / p50, prediluted
  • Tested applicationsIHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (Human) (N terminal).

  • Positive control
    • Testis, tonsil and prostate.

Properties

Applications

Our Abpromise guarantee covers the use of ab15485 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent dilution. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Target

  • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
  • Sequence similaritiesContains 7 ANK repeats.
    Contains 1 death domain.
    Contains 1 RHD (Rel-like) domain.
  • DomainThe C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
    Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
  • Post-translational
    modifications
    While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
    Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
    Polyubiquitination seems to allow p105 processing.
    S-nitrosylation of Cys-61 affects DNA binding.
  • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
  • Information by UniProt
  • Database links
  • Alternative names
    • DKFZp686C01211 antibody
    • DNA binding factor KBF1 antibody
    • DNA binding factor KBF1 EBP1 antibody
    • DNA binding factor KBF1 EBP1 antibody
    • DNA-binding factor KBF1 antibody
    • EBP 1 antibody
    • EBP-1 antibody
    • EBP1 antibody
    • KBF1 antibody
    • MGC54151 antibody
    • NF kappa B antibody
    • NF kappabeta antibody
    • NF kB1 antibody
    • NFKB 1 antibody
    • NFKB p105 antibody
    • NFKB p50 antibody
    • NFKB1 antibody
    • NFKB1_HUMAN antibody
    • Nuclear factor kappa B DNA binding subunit antibody
    • Nuclear factor NF kappa B p105 subunit antibody
    • Nuclear factor NF kappa B p50 subunit antibody
    • Nuclear factor NF-kappa-B p50 subunit antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody
    • p84/NF-kappa-B1 p98 antibody
    see all

Anti-NFkB p105 / p50 antibody, prediluted images

  • ab15485 staining NFkB p50 in human tonsil by Immunohistochemistry (FFPE-sections).

References for Anti-NFkB p105 / p50 antibody, prediluted (ab15485)

ab15485 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your equiry. For ab7970, our source for this antibody was able to provide me with the following information: "I am sorry, but I do not have any data that suggests a bias for bound or unbound. So for now I can only say that it will defini...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"